Tetraphase (NASDAQ: TTPH) is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections; its lead product XERAVATM (eravacycline) is approved for the treatment of complicated intra-abdominal infections by the FDA and EMA. Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceutical Company.
Sector: Life Sciences
Symbiomix
Symbiomix developed the first oral, single dose treatment in the United States for bacterial vaginosis (BV), a common gynecological infection that increases the risk of serious health problems. Symbiomix was acquired by Lupin Pharmaceuticals.
RespiVert
RespiVert was a drug discovery and development company focused on inhaled therapies for severe respiratory disease. RespiVert was acquired by Centocor Ortho Biotech – a division of Johnson & Johnson.
ReGenX Biosciences
ReGenX Biosciences (NASDAQ: RGNX) is a leading AAV (adeno-associated virus) gene therapy company with a broad platform technology based on its proprietary NAV vector technology platform.
Pulmocide
Pulmocide is a biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life.
Proteostasis Therapeutics
Proteostasis Therapeutics (NASDAQ: PTI) is a drug discovery company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Proteostasis Therapeutics merged with Yumanity Therapeutics in 2020.
NovaMed Pharmaceuticals
NovaMed Pharmaceuticals is a revenue-generating specialty pharmaceutical company focused on the commercialization of branded innovative therapies for diseases with high unmet medical need in China, including oncology, urology, and cardiovascular. NovaMed was acquired by SciClone.
NextWave Pharmaceuticals
NextWave Pharmaceuticals is a specialty pharmaceutical company seeking to create and promote differentiated products in the pediatric market. NextWave Pharmaceuticals was acquired by Pfizer.
Mersana Therapeutics
Mersana Therapeutics (NASDAQ: MRSN) has its lead product candidate, XMT-1536, in clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
LigoCyte
LigoCyte Pharmaceuticals was a vaccine discovery and development company with a first-in-class vaccine for norovirus, a pathogen that is a leading cause of viral gastroenteritis (stomach flu). LigoCyte Pharmaceuticals was acquired by Takeda.